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We have developed an in vitro mutation assay
using primary hepatocytes from the transgenic
Muta
TMMouse. Primary hepatocytes were isolated
using a two-step perfusion method with puriﬁca-
tion by Percoll, cultured, and treated with ben-
zo[a]pyrene (BaP), 2-amino-1-methyl-6-phenyl-
imidazo[4,5-b]pyridine (PhIP), 3-nitrobenzoan-
throne (3-NBA), and cigarette smoke condensate
(CSC). The mean lacZ mutant frequency (MF) for
the solvent control was approximately twofold
greater than the spontaneous MF observed in liver
tissue. A concentration-dependent increase in MF
(up to 3.7-fold above control) was observed fol-
lowing exposure to BaP. Fourfold and twofold
increases in mutant frequency were observed for
3-NBA and PhIP exposures, respectively, without
the addition of any exogenous metabolic activa-
tion. A slight but statistically signiﬁcant increase in
lacZ MF was observed for CSC, but only at the
lowest concentration. This is the ﬁrst report
demonstrating that mutations can be detected in
cultured primary hepatocytes from Muta
TMMouse.
The preliminary results presented suggest that
the Muta
TMMouse primary hepatocyte mutagenic-
ity assay can be used as a cost-effective tool for
screening of environmental mutagens and thera-
peutic products. Environ. Mol. Mutagen. 51:330–
337, 2010. V V C 2009 Wiley-Liss, Inc.
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INTRODUCTION
Transgenic rodent (TGR) mutation models such as
Muta
TMMouse and Big Blue
1 rat/mouse provide efﬁcient
methods for quantitative assessments of in vivo gene
mutation. Such transgenic mutation assays involve scoring
of mutations at transgenic lacZ or lacI sequences carried
on a lambda phage shuttle vector that has been stably
integrated into the rodent genome. The shuttle vectors
containing the transgenic targets exist in every cell of the
transgenic animal and are easily recovered from genomic
DNA using a convenient in vitro packaging system
[Gossen et al., 1989; Kohler et al., 1991; Douglas et al.,
1996]. A major advantage of the transgenic mutation sys-
tem lies in its ability to provide reliable and reproducible
assessments of in vivo mutagenicity in any organ or tissue
[Heddle et al., 2000; Nohmi et al., 2000; Thybaud et al.,
2003]. In their detailed review paper, Lambert et al. con-
cluded that TGR mutation models showed excellent con-
cordance (77%) with rodent carcinogenicity that meets or
exceeds what has been observed for other genotoxicity
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Environmental andMolecularMutagenesis51:330^337(2010)assays commonly employed for regulatory decision-mak-
ing (e.g., bone marrow micronuclei or unscheduled DNA
synthesis in liver) [Thybaud et al., 2003; Lambert et al.,
2005].
Although in vivo TGR mutagenicity assays offer the
advantages of utility for regulatory screening, matching in
vitro versions provide an opportunity for high-throughput
analyses of test mutagens (e.g., new chemicals or drug
candidates). A number of approaches have been employed
to establish cell lines derived from TGRs. For example, a
Big Blue
1 mouse embryonic ﬁbroblast cell line was
derived from primary embryo cells immortalized and
transformed by X-ray irradiation and benzo[a]pyrene
(BaP) exposure [Erexson et al., 1998]. BBR1 and BBM1
cells were derived from the primary skin ﬁbroblasts of the
Big Blue
1 rodents [Erexson et al., 1999]. Several epithe-
lial and ﬁbroblast cell lines have been derived from the
rat mammary gland and oral cavity, and these cells were
immortalized by exposure to the alkylating agent N-ethyl-
N-nitrosourea [McDiarmid et al., 2001; Papp-Szabo ´ et al.,
2003]. Watanabe et al. [2001] established two mammary
carcinoma cell lines derived from 2-amino-1-methyl-6-
phenyl-imidazo[4,5-b]pyridine (PhIP)-induced Big Blue
1
rat mammary adenocarcinomas. Finally, a spontaneously
immortalized epithelial cell line, known as FE1, was
derived from Muta
TMMouse lung tissue. The FE1 line has
proved to be a useful tool for rapid and effective screen-
ing of environmental mutagens [White et al., 2003; Jacob-
sen et al., 2007, 2008a,b; Berndt-Weis et al., 2009].
The aforementioned cell lines, and indeed all cell lines
derived from nonhepatic tissue, have a limited endogenous
capacity to metabolize test mutagens. In general, trans-
formed cell lines lose their capacity to metabolize or acti-
vate promutagens. Some researchers have even reported a
lack of sensitivity for the widely used hepatic HepG2 cells,
in comparison with primary human hepatocytes [Wilkening
et al., 2003]. Consequently, an exogenous metabolic acti-
vation mixture (e.g., postmitochondrial supernatant from
Aroclor-induced rat liver) is often required to permit Phase
I metabolism and conversion of promutagens into reactive
metabolites. For example, an exogenous S9 mixture from
rat liver was required in a study that investigated the muta-
genic activity of PhIP in the BBR/MFib ﬁbroblast system
[McDiarmid et al., 2002].
The liver is the primary organ for the metabolism of
xenobiotic substances by Phase I and Phase II biotransfor-
mation enzymes. Cultured primary mammalian hepato-
cytes can retain the characteristics of liver cells and have
been shown to contain a broad spectrum of xenobiotic
metabolizing enzymes [Ulrich et al., 1995]. The metabolic
capacity of cultured primary mammalian hepatocytes sug-
gests that they should be ideal for the evaluation and
screening of suspected environmental mutagens. Indeed,
the utility of cultured primary hepatocytes has already
been deﬁnitively demonstrated in general toxicology and
for early screening of drug candidates [Ulrich et al.,
1995]. However, the established hepatic assays for geno-
toxicity screening (e.g., unscheduled DNA synthesis,
DNA adducts/repair) do not require the property of cell
proliferation [Casciano 2000].
In vitro gene mutation assays are generally carried out
with continuously dividing cells, despite their distinct
metabolic insufﬁciency. The lack of mitogenesis, and
thus, the limited capacity for cell division of primary
hepatocytes, has prevented their use for the scoring of
gene mutations. However, recent advances in cell culture
techniques can permit limited proliferation of primary
hepatocytes, and primary hepatocyte cultures have been
employed to assess induction of sister chromatid
exchanges and micronuclei [Eckl and Raffelsberger, 1997;
Mu ¨ller-Tegethoff et al., 1997]. Several studies have
shown that the addition of selected growth factors and
hormones (e.g., insulin, epidermal growth factor [EGF] or
hepatocyte growth factor [HGF]) can induce proliferation
of primary hepatocytes in vitro [Matsumoto and
Nakamura, 1991; Block et al., 1996; Mu ¨ller-Tegethoff
et al., 1997]. In this pilot study, we demonstrate
that cultured primary hepatocytes derived from the
Muta
TMMouse can be employed to assess the mutagenic
activity of selected test mutagens that require metabolic
activation by cytochrome P450 isozymes.
MATERIALS ANDMETHODS
Materials and Reagents
All cell culture media and reagents were purchased from Sigma-
Aldrich (Oakville, ON, Canada). 3-Nitrobenzoanthrone (3-NBA) was
obtained from the Sigma Library of Rare Chemicals (Oakville, ON,
Canada). BaP was obtained from Supelco Canada (Mississauga, ON,
Canada) and PhIP was obtained from Toronto Research Chemicals
(Downsview, ON, Canada). Preparation of the cigarette smoke conden-
sate (CSC) was performed at Labstat International Inc. (Kitchener, ON,
Canada). Combustion (i.e., smoking) of commercially available full ﬂa-
vor cigarettes was carried out on a 20-port rotary smoking machine (see
Moir et al. [2008] for details). The smoking parameters and smoking
machine speciﬁcations followed the International Organization for Stand-
ardization’s standard ISO 3308 (i.e., Routine Analytical Cigarette-Smok-
ing Machines Deﬁnitions and Standard Conditions) (see Moir et al.
[2008]). Mainstream smoke was passed through a 92-mm glass ﬁber ﬁl-
ter disc for particulate matter collection. To prepare tobacco smoke con-
densates, ﬁlter pads were placed in a ﬂask containing dimethyl sulfoxide
(DMSO) (ACS spectrophotometric grade, >99.9%) and shaken on a
wrist-action shaker (Barnstead International, Melrose Park, IL) for
20 min. Each sample was standardized to a concentration of 30 mg total




TMMouse (BALB/c 3 DBA2, mouse strain 40.6)
was developed using a bacteriophage lambda shuttle vector containing
the bacterial lacZ gene as a target for mutation detection [Gossen et al.,
1989]. The transgenic mice were bred and maintained at Health Canada
facilities under conditions approved by the Health Canada Animal Care
Committee.
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and ChemicalTreatment
Two 18–22-week-old male lacZ transgenic mice were used in this
pilot study. Primary hepatocytes were isolated from Muta
TMMouse by an
adaptation of a two-step collagenase perfusion technique that involves
enrichment prior to culturing using Percoll isodensity puriﬁcation
[Seglen, 1976; Kreamer et al., 1986; Tateno et al., 2000; Chen and
Bunce, 2003]. A schematic of the procedure employed for isolation of
parenchymal hepatocytes is provided in Figure 1. In brief, the mice were
anesthetized by an i.p. injection of 100 mg/kg pentobarbital. The caudal
vena cava was catheterized, the liver perfused with Hank’s balanced salt




3, or phenol red)
containing 1 mM ethylene glycol tetraacetic acid and 10 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) for  2 min,
followed by hepatocyte-qualiﬁed collagenase (0.3 mg/ml) in William’s E
medium (pH 7.4), supplemented with 10 mM HEPES and 0.1 mg/ml al-
bumin, for  10 min. The digested liver was then excised, rinsed, and
disaggregated in a 150-mm polystyrene Petri dish. The material was ﬁl-
tered through sterile gauze, and the ﬁltrate was gently centrifuged for 3
min at 50g. The pellet was resuspended in 10 ml attachment medium
(William’s E medium supplemented with 10 mM HEPES, 2 mM L-gluta-
mine, and 10% fetal bovine serum) combined with 10 ml of Percoll in
HBSS and recentrifuged at 50g for 10 min. After the enrichment by
Percoll isodensity puriﬁcation, the cells were washed and gently centri-
fuged, and the pellets were resuspended in  20 ml of attachment media.
The cells were counted using a hemocytometer. The viability of the cells
was >90% as assessed by the trypan blue dye exclusion method.
The cells were placed (2.5 3 10
5 cells/3.0 ml attachment media) in
60-mm polystyrene tissue culture dishes (Corning, Corning, NY) pre-
coated with collagen. After 2 hr, the attachment medium was removed
and 3.0 ml serum-free medium (William’s E medium supplemented with
10 mM HEPES, 2 mM L-glutamine, 10 mM pyruvate, 0.35 mM proline,
20 units/l insulin, 100 units/ml penicillin G, 100 mg/ml streptomycin sul-
phate) containing 1 ng/ml murine EGF was added to each plate. The
cells were then incubated at 378C (95% relative humidity, 5% CO2).
After 12 hr the cells were treated with various concentrations of test
mutagens in serum-free medium containing 1 ng/ml EGF for 6 hr. After
treatment, the cells were washed with phosphate-buffered saline (pH 7.6)
and incubated in serum-free medium containing 1 ng/ml EGF for 48 hr
before mutation scoring.
Isolation ofGenomic DNA
Genomic DNA was isolated as previously described [Vijg and
Douglas, 1996; Douglas et al., 1999], with modiﬁcations for cultured
cells [White et al., 2003]. Brieﬂy, treated cells were digested overnight
Environmental and Molecular Mutagenesis. DOI 10.1002/em
Fig. 1. Scheme showing the procedure employed to isolate nearly pure hepatocytes via two-step perfusion
and Percoll isodensity centrifugation (Adapted from the works of Seglen [1976], Kreamer et al. [1986], Block
et al. [1996], Tateno et al. [2000], and Kruglov et al. [2002]).
332 Chen et al.in lysis buffer at 378C (10 mM Tris, pH 7.6, 150 mM NaCl, 10 mM eth-
ylenediaminetetraacetic acid [EDTA], with 1% sodium dodecyl sulphate
and 1 mg/ml fresh proteinase K), and lysates extracted with phenol/chlo-
roform (1:1), followed by chloroform. Potassium acetate was added to a
ﬁnal concentration of 1.6 M and the DNA was precipitated in ethanol.
DNA was spooled onto a sealed Pasteur pipette, washed with 70% etha-
nol, placed in 15–25 ll of Tris-EDTA buffer (10 mM Tris, pH 7.6, 0.1
mM EDTA), and stored at 48C for further analysis.
lacZ MutantFrequencyAnalysis
Transgene mutant frequency (MF) was determined using the
phenyl-b-D-galactopyranoside (P-gal)–positive selection assay [Vijg and
Douglas, 1996; Lambert et al., 2005]. The method employs galE
2 host
bacteria to facilitate the isolation and enumeration of mutant copies of
the lacZ transgene [Gossen et al., 1992]. kgt10lacZ DNA copies were
rescued from genomic Muta
TMMouse DNA (4 ll aliquots) using the
Transpack
TM lambda packaging system (Stratagene, La Jolla, CA). Pack-




2, pAA119 with galT and galK) [Gossen et al.,
1992] and plated on minimal agar with 0.3% (w/v) P-gal. Concurrently,
bacteria were plated on nonselective minimal agar to enumerate total
plaque-forming units (pfu) or titer. All plates were incubated overnight
at 378C. MF was expressed as the ratio of mutant plaques to total pfu.
The data presented are summaries across numerous experimental repli-
cates. MF and pfu values are readily available from the corresponding
author.
StatisticalAnalysis
MF data were analyzed by Poisson regression using SAS version
9.1 (SAS Institute, Cary, NC), and the data were ﬁt to the model
log(E(Yi)) 5 log ti 1b xi, where E(Yi) is the expected value for the
ith observation, b is the vector of regressions coefﬁcients, xi is a vec-
tor of covariates for the ith observation, and ti is the offset variable
used to account for differences in observation count period (i.e., pfu).
The offset (i.e., natural log of pfu) was given a constant coefﬁcient
of 1.0 for each observation, and log-linear relationships between mu-
tant count and test mutagen concentration were speciﬁed by a natural
log link function. Type 1, or sequential analysis, was employed to
examine the statistical signiﬁcance of the chemical treatment, and cus-
tom contrasts were employed to evaluate the statistical signiﬁcance of
responses at selected concentrations. Custom contrasts were accom-
plished by specifying an L matrix, and computing statistics for pair-




Figure 2 illustrates the phenotypic changes of hepato-
cytes cultured in the presence of EGF. The freshly iso-
lated mouse hepatocytes display typical cubic, nonprolif-
erating morphology 2 hr after being plated (Fig. 2A).
Both mononuclear and binuclear parenchymal hepatocytes
were observed in the isolated cell populations. After 48 hr
culture in serum-free medium supplemented with EGF,





The overall MF for the vehicle control was 14.2 6 5.6
3 10
25. This value is approximately twofold greater than
that commonly observed in Muta
TMMouse tissues (i.e.,
5.9 3 10
25) [White et al., 2003]. In the initial pilot
experiment (hepatocytes from two male mice), 1 ng/ml
HGF was employed to stimulate hepatocyte growth, and
the results revealed substantial inductions of lacZ mutants
by 1.58 lM BaP (29.7 3 10
25) and 4 lM PhIP (30.8 3
10
25). These results conﬁrmed the feasibility of the assay
system. However, all subsequent experiments were con-
ducted using EGF, a culture reagent that is far less expen-
sive than HGF.
Muta
TMMouse primary hepatocytes cultured in the
presence of EGF were treated with several known envi-
ronmental promutagens including BaP, PhIP, 3-NBA, and
CSC. A summary of the MF values for these agents is
presented in Table I. A concentration-dependent increase
in MF (up to 3.7-fold above the concurrent control) was
observed for primary hepatocytes exposed to BaP concen-
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Fig. 2. Phase-contrast photomicrographs of cultured primary hepato-
cytes. (A) Typical cubic hepatocytes shortly after isolation; (B) scattered,
elongated hepatocytes after 48 hr (magniﬁcation, 403).
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dependent increase in MF was also observed for PhIP,
with the maximum response about 2.6-fold above control
at the highest concentration tested (8 lM). At the low and
middle concentrations (i.e., 1.45 and 3.63 lM), 3-NBA
exposure induced a more than fourfold increase in MF;
however, at the highest concentration (18.15 lM), cyto-
toxicity contributed to a low DNA recovery, and reliable
MF scoring was not possible. For the CSC exposure, a
statistically signiﬁcant increase in MF was observed
at the low concentration (80 lg TPM/ml); however, no
signiﬁcant increase was observed for the higher concen-
trations (i.e., 120, 160 lg/ml).
DISCUSSION
This study introduces a novel in vitro assay system for
mutagenicity assessment that takes simultaneous advant-
age of the P-gal–positive selection system to score muta-
tions at the lacZ transgene, and the metabolic capacity of
primary hepatocytes. Although hepatocytes have a limited
capacity for cell proliferation, EGF supplementation was
employed to stimulate growth and division, and micro-
scopic observations showed cell elongation and
proliferation. Earlier works by Ichihara et al. [1982] and
Nakamura and Ichihara [1985] have shown that mature
hepatocytes, which are usually quiescent, will synthesize
DNA and show density-dependent growth when cultured
in the presence of insulin and EGF. Moreover, the work
by Mu ¨ller-Tegethoff et al. demonstrated the utility of
cultured primary hepatocytes for the assay of micronuclei
[Mu ¨ller-Tegethoff et al., 1997]. This work extends the
application of hepatocytes for genetic toxicity assessment.
Hepatocytes are the main functional liver cells, and
they make up at least 60% of the cytoplasmic mass of the
liver [Seglen, 1976]. In addition to hepatocytes, liver tis-
sue contains endothelial cells, bile duct cells, Stellate
cells, Kupffer cells, as well as supporting tissues. The
standard two-step collagenase perfusion method employed
in this study has been shown to yield 98% parenchymal
hepatocytes, and the remaining 2% consisting of nonpar-
enchymal cells (e.g., endothelial cells, bile duct cells,
Stellate cells, Kupffer cells) can be separated by centrifu-
gation (Fig. 1) [Seglen, 1976; Block et al., 1996; Tateno
et al., 2000]. In our experiment, the isolated cells showed
a homogeneous cubic morphology typical of nonprolifer-
ating hepatocytes (Fig. 2A); however, after 48 hr incuba-
tion with EGF the cultured cells displayed a scattered
morphology (Fig. 2B), and this morphology is consistent
with the observations of Block et al. [1996]. Moreover,
Tateno et al. have shown that isolated hepatocytes, such
as those shown in Figure 2, can be highly heterogeneous
with respect to size and proliferation potential [Tateno
et al., 2000]. Although it is possible that some ﬁbroblasts
coexist with the isolated hepatocytes and contribute to the
measured MF values, it is important to note that liver
ﬁbroblasts are present mainly in the hepatic hilum, and
the isolation of ﬁbroblasts from the hilum requires the use
of a different enzyme (i.e., pronase) [Kruglov et al.,
2002]. Furthermore, the ﬁrst centrifugation step employed
in this study will effectively separate ﬁbroblasts from
Environmental and Molecular Mutagenesis. DOI 10.1002/em

















Solvent control 0 11 66 503,461 14.2 5.6
BaP 1.58 5 78 286,935 27.5 11.3 0.0006
3.17 5 71 217,852 35.4 17.9 <0.0001
6.34 5 149 286,106 53.1 8.0 <0.0001
Poisson regression chi-square for test mutagen concentration effect 5 61.7, P < 0.0001
PhIP 2.0 5 38 168,483 22.1 6.8 0.015
4.0 5 75 241,211 30.7 5.9 <0.0001
8.0 5 39 130,380 36.8 17.5 0.0002
Poisson regression chi-square for test mutagen concentration effect 5 28.2, P < 0.0001
3-NBA 1.45 5 62 119,777 56.6 14.8 <0.0001
3.63 3 26 32,139 79.4 19.5 <0.0001
Poisson regression chi-square for test mutagen concentration effect 5 70.6, P < 0.0001
CSC 80 5 46 198,966 23.1 6.6 0.005
120 5 44 300,188 15.1 7.4 NS
f
160 4 21 110,831 18.8 4.5 NS
Poisson regression chi-square for test mutagen concentration effect 5 8.8, P 5 0.03
aAll concentrations in lM, except CSC, which is expressed as lg TPM/ml.
bn, the number of assays for mutation scoring.
cMean lacZ mutant frequency per 10
5 pfu.
dSD, standard deviation of the mean.
ePoisson regression with custom contrasts against the solvent control.
fNS, not signiﬁcant.
334 Chen et al.hepatocytes. Thus, if ﬁbroblasts are present in the isolated
cell population, they would be expected to occur in trace
amounts (see Fig. 1). Consequently, the isolated DNA
employed for mutation scoring is mainly from hepato-
cytes, and not ﬁbroblast contamination. Nevertheless, sub-
sequent analyses should employ biochemical methods to
investigate the composition of the isolated cell population
(see discussion below).
BaP has been frequently used as a prototypical promu-
tagenic carcinogen, and the observed increase in MF in
the cultured Muta
TMMouse hepatocytes employed in this
study (i.e., 3.7-fold) is consistent with the results of in
vivo studies. Although liver is not necessarily the target
organ for BaP-induced neoplasia, up to a ﬁvefold increase
of lacZ gene MF (i.e., 22 3 10
25 vs. 4.1 3 10
25 in
corn oil control) has been observed in the liver of
Muta
TMMouse orally exposed to BaP at 125 mg/kg/day
for 5 days, followed by a 14-day manifestation time
[Hakura et al., 1998]. And threefold induction of MF (i.e.,
62.5 3 10
25 vs. 22.8 3 10
25 in the corn oil control) was
seen in a subsequent study employing a 6-month manifes-
tation period [Hakura et al., 1999]. Although differences
in the exposure kinetics of in vitro and in vivo systems
prohibit direct comparisons of MF values, the similarity
in the trends highlights the utility of the in vitro system
based on cultured primary hepatocytes.
PhIP, a heterocyclic aromatic amine identiﬁed in
cooked foods, is a potent mutagen and animal carcinogen.
Cytochrome P450 isozymes 1A1, 1A2, and 1B1 are
believed to be involved in the metabolism and activation
of PhIP via N-hydroxylation, followed by esteriﬁcation to
form N-acetoxy-PhIP that ultimately yields the highly
reactive nitrenium ion [Boobis et al., 1994; Crofts et al.,
1998]. PhIP is mutagenic in Salmonella and induces DNA
damage, gene mutations, and cytogenetic abnormalities in
cultured mammalian cells in the presence of an exogenous
S9 metabolic activation system [IARC, 1993; Felton
et al., 1994]. It has been documented that PhIP induced
increases in MF in the liver of transgenic animals [Lynch
et al., 1996; Masumura et al., 1999; Klein et al., 2001].
Our earlier in vitro work with the Muta
TMMouse FE1 epi-
thelial cell line showed PhIP-induced increases in lacZ
MF only in the presence of exogenous S9 [White et al.,
2003]. In this study, a concentration-dependent increase
in MF was observed in cultured Muta
TMMouse hepato-
cytes exposed to PhIP, and the observed increase (i.e.,
2.6-fold) is consistent with the aforementioned results.
3-NBA is one of the most potent mutagens isolated
from diesel emission particulates. Metabolism and activa-
tion of 3-NBA in mammalian systems is complex and
believed to involve nitroreduction by NAD(P)H:quinone
oxidoreductase and/or xanthine oxidase [Arlt et al., 2005;
Chen et al., 2008]. TGR mutagenicity assessments
revealed up to 4.8-fold induction in cII MF in
Muta
TMMouse liver after intraperitoneal treatment with 3-
NBA (25 mg/kg body weight, administered once per
week for 4 weeks) [Arlt et al., 2004]. Similarly, our ear-
lier work showed a 4.2-fold induction in lacZ mutant fre-
quency in Muta
TMMouse liver following oral administra-
tion of 2 mg/kg/day for 28 days [Chen et al., 2008]. The
increase in lacZ gene MF observed in this study (i.e., 5.6-
fold) is consistent with these results.
Tobacco smoke is the most extreme example of a ‘‘sys-
temic human mutagen’’ [DeMarini, 2004]. CSC has been
shown to induce mutations at the tk locus in mouse lym-
phoma cells [Clive et al., 1979] and Hprt mutations in
CHO cells [Jongen et al., 1985] in the presence of exoge-
nous metabolic activation. Hprt mutations have also been
observed in a human lymphoblastoid cell line (MCL-5)
that carries two recombinant plasmids expressing
xenobiotic metabolizing enzymes [Krause et al., 1999].
There are more than 60 carcinogens in cigarette smoke,
including several tobacco-speciﬁc nitrosamines such
as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and
N0-nitrosonornicotine, several polycyclic aromatic hydro-
carbons (e.g., BaP), and aromatic amines such as
4-aminobiphenyl [Hecht, 2003]. Numerous studies have
established that these carcinogens require metabolic acti-
vation by several cytochrome P450 isozymes [Hecht,
2008]. The results obtained here (Table I) demonstrate
that 80 lg TPM/ml induced a signiﬁcant increase in lacZ
MF in cultured Muta
TMMouse hepatocytes. The lack of
mutagenicity observed at higher concentrations (i.e.,
120, 160 lg/ml) was likely the result of cytotoxicity,
which was evidenced by reduced cell survival and low
yield of extractable DNA.
The results presented here conﬁrm the utility of a lacZ
gene mutation assay in cultured primary hepatocytes
derived from the Muta
TMMouse for in vitro screening of
suspected environmental mutagens. This in vitro mamma-
lian cell assay system has several noteworthy advantages:
(1) signiﬁcant reduction in the number of animals
required for mutagen screening relative to in vivo studies;
(2) the metabolic competence of primary hepatocytes and
concomitant ability to metabolize and activate several
types of promutagens; (3) nearly pure populations of fresh
hepatocytes are relatively easy to obtain and culture;
(4) the Muta
TMMouse system for scoring lacZ mutations
is well established and validated. In addition, the use of
primary hepatocytes readily permits comparisons of the
metabolism of chemicals across species, thus increasing
the conﬁdence of extrapolations from animals to humans
[NRC, 2007].
Nevertheless, it should be noted that this work consti-
tutes a pilot study, and follow-up work will be required to
reﬁne, validate, and optimize an assay based on cultured
primary hepatocytes. There are numerous avenues for
follow-up research. First, subsequent analyses should rig-
orously investigate the composition of the isolated cell
population. To this end, biochemical tools, such as those
Environmental and Molecular Mutagenesis. DOI 10.1002/em
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to provide an enzymatic and proteomic proﬁle of the
isolated cells (e.g., total cytochrome P450 content, activ-
ity of selected P450 isozymes). As ﬁbroblasts can prolif-
erate in the absence of EGF, experiments conducted both
in the presence and in the absence of EGF could permit
an assessment of ﬁbroblast contamination. Second, subse-
quent analyses should reﬁne and optimize the assay proto-
col. For example, the magnitude and reproducibility of
the response to selected mutagens could be assessed for
cell populations derived from numerous animals, includ-
ing very young animals (e.g., 14 days), as well as animals
exposed to chemical inducers of liver enzymes (e.g.,
Aroclor). The former would be expected to maximize the
proliferation potential of the isolated cells, and the latter
would be expected to increase the metabolic capacity of
the isolated cells. In addition, a larger culture surface
could be employed to permit an increase in the number of
exposed cells. Finally, subsequent analyses could employ
established cytotoxicity-assessment tools (e.g., clonal sur-
vival) to reliably quantify effects that prevent or retard
cell growth and proliferation.
In summary, we have developed and introduced an in
vitro mutation bioassay based on cultured primary hepato-
cytes from the transgenic Muta
TMMouse, and preliminary
results indicate that the assay can be employed as a cost-
effective complement to in vivo analyses for screening of
environmental mutagens. The assay system can quantify
mutations at the transgenic lacZ locus (this work), as well
as the smaller cII locus. The latter can be more readily
subjected to sequence analysis. Moreover, these endpoints
can readily be combined with other genotoxicity end-
points, including DNA strand breaks (i.e., comet), micro-
nucleus formation, and unscheduled DNA synthesis.
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